Nasdaq: VRTXVertex Pharmaceuticals

    Vertex Pharmaceuticals: results and news

    Every Vertex Pharmaceuticals filing with the US SEC that Blacklitt has written about, explained in plain words and linked to the filing, newest first: earnings.

    1 article · Health Care · Latest 3 Nov 2026

    Two people in protective gowns and face masks work at laboratory glassware in a sterile black-and-white laboratory

    Nasdaq: VRTXVertex Pharmaceuticals

    Vertex Pharmaceuticals Q3 2026 Results: Net Income $654 Million on Revenue of $3.44 Billion

    Vertex Pharmaceuticals (Nasdaq: VRTX) reported third quarter 2026 GAAP revenue of $3.44 billion and GAAP net income of $653.6 million, and it said on 2 Nov 2026 that the results cover the three months to 30 Sep 2026. GAAP diluted EPS was $2.56, and the company's adjusted diluted EPS, a company-defined measure that excludes items such as stock-based compensation, was $4.76.

    • US stocks
    • Earnings

    Blacklitt Research3 min read